162 related articles for article (PubMed ID: 31390951)
1. Fear, fight, familiarize: the experiences of people living with relapsing-remitting multiple sclerosis and taking oral medication.
Van Reenen E; Van Der Borg W; Visse M; Van Der Meide H; Visser L
Int J Qual Stud Health Well-being; 2019 Dec; 14(1):1648946. PubMed ID: 31390951
[No Abstract] [Full Text] [Related]
2. The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.
Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
Patient; 2020 Oct; 13(5):583-597. PubMed ID: 32588337
[TBL] [Abstract][Full Text] [Related]
3. "Always looking for a new balance": toward an understanding of what it takes to continue working while being diagnosed with relapsing-remitting multiple sclerosis.
Meide HV; Gorp DV; van der Hiele K; Visser L
Disabil Rehabil; 2018 Oct; 40(21):2545-2552. PubMed ID: 28639482
[TBL] [Abstract][Full Text] [Related]
4. Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study.
Sippel A; Riemann-Lorenz K; Scheiderbauer J; Kleiter I; Morrison R; Kofahl C; Heesen C
BMC Health Serv Res; 2021 Oct; 21(1):1141. PubMed ID: 34686166
[TBL] [Abstract][Full Text] [Related]
5. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
[TBL] [Abstract][Full Text] [Related]
6. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Thomas RH; Wakefield RA
Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
[TBL] [Abstract][Full Text] [Related]
7. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
[TBL] [Abstract][Full Text] [Related]
8. "Taming the Beast": Exploring the Lived Experience of Relapsing Remitting Multiple Sclerosis Using a Life History Approach.
Burke T; Vucic S; Patching J
Res Theory Nurs Pract; 2019 Aug; 33(3):229-245. PubMed ID: 31615943
[TBL] [Abstract][Full Text] [Related]
9. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
10. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
11. Oral disease-modifying therapies for multiple sclerosis in the Middle Eastern and North African (MENA) region: an overview.
Deleu D; Mesraoua B; Canibaño B; Melikyan G; Al Hail H; El-Sheikh L; Ali M; Al Hussein H; Ibrahim F; Hanssens Y
Curr Med Res Opin; 2019 Feb; 35(2):249-260. PubMed ID: 29764226
[TBL] [Abstract][Full Text] [Related]
12. Laquinimod for multiple sclerosis.
He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
[TBL] [Abstract][Full Text] [Related]
13. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
[TBL] [Abstract][Full Text] [Related]
14. First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence.
Ferraro D; Camera V; Baldi E; Vacchiano V; Curti E; Guareschi A; Malagù S; Montepietra S; Strumia S; Santangelo M; Caniatti L; Foschi M; Lugaresi A; Granella F; Pesci I; Motti L; Neri W; Immovilli P; Montanari E; Vitetta F; Simone AM; Sola P
Curr Med Res Opin; 2018 Oct; 34(10):1803-1807. PubMed ID: 29526118
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
17. "I'm walking into the unknown": Qualitative insights into how emotions and lived experience related to multiple sclerosis diagnosis impact on decisions to pursue disease modifying treatment.
Carey G; Wilson N; Janssen J; Chohan A; Rog D; Roddam H
Mult Scler Relat Disord; 2022 Feb; 58():103464. PubMed ID: 34952250
[TBL] [Abstract][Full Text] [Related]
18. Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.
Cutter G; Veneziano A; Grinspan A; Al-Banna M; Boyko A; Zakharova M; Maida E; Pasic MB; Gandhi SK; Everts R; Cordioli C; Rossi S
Mult Scler Relat Disord; 2019 Aug; 33():13-21. PubMed ID: 31132664
[TBL] [Abstract][Full Text] [Related]
19. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
